In the Claims

1. (Currently Amended) A method of inhibiting angiogenesis, ~~or~~ tumor invasion, or formation of metastases in a mammal comprising:

administering a therapeutically effective amount of ~~an active agent selected from the group consisting of a protein substance comprising all or part of a disintegrin domain of an adamalysin or a derivative thereof,~~ a nucleic acid molecule comprising a polynucleotide sequence coding a polypeptide comprising all or part of the disintegrin domain of an adamalysin or a derivative ~~thereof~~ of the disintegrin domain of an adamalysin to the mammal, wherein the disintegrin domain contains an RGD sequence and the polypeptide can inhibit migration and proliferation of endothelial cells, adhesion of endothelial cells to matrix substrates and formation of capillary structures.

2. (Previously Presented) The method according to claim 1, wherein the adamalysin is metargidin.

3. (Withdrawn) The method according to claim 2, wherein the protein substance comprises all or part of the disintegrin domain of metargidin and having an amino-acid sequence of SEQ ID NO. 2 or a derivative thereof.

4. (Currently Amended) The method according to claim 2, wherein the nucleic acid molecule comprises a polynucleotide sequence ~~coding all or part of the disintegrin domain of metargidin and having a nucleotide sequence~~ of SEQ ID NO. 1, or a complementary sequence ~~or a derivative thereof~~.

5. (Currently Amended) The method according to claim 4, wherein the nucleic acid molecule ~~comprises a vector or is joined to a vector of expression~~ is inserted into an expression vector.

6. (Previously Presented) The method according to claim 4, wherein the nucleic acid molecule is present in cells transformed by said molecule in a manner to express all or part of the disintegrin domain *in vivo*.

7. (Previously Presented) The method according to claim 5, wherein the nucleic acid molecule is present in cells transformed by said molecule in a manner to express all or part of the disintegrin domain *in vivo*.

8. (Currently Amended) A method of treating cancer in a mammal comprising administering a therapeutically effective amount of ~~an active agent selected from the group consisting of a protein substance comprising all or part of a disintegrin domain of an adamalysin or a derivative thereof and~~ a nucleic acid molecule comprising a polynucleotide sequence coding all or part of the disintegrin domain of an adamalysin or a derivative ~~thereof~~ of the disintegrin domain of an adamalysin to the mammal, wherein the disintegrin domain contains an RGD sequence and the polypeptide can inhibit migration and proliferation of endothelial cells, adhesion of endothelial cells to matrix substrates and formation of capillary structures.

9. (Currently Amended) A method of treating inflammatory diseases in a mammal comprising administering a therapeutically effective amount ~~of an active agent selected from the~~

~~group consisting of a protein substance comprising all or part of a disintegrin domain of an adamalysin or a derivative thereof and~~ a nucleic acid molecule comprising a polynucleotide sequence coding a polypeptide comprising all or part of the disintegrin domain of an adamalysin or a derivative ~~thereof~~ of the disintegrin domain of an adamalysin to the mammal, wherein the disintegrin domain contains an RGD sequence and the polypeptide can inhibit migration and proliferation of endothelial cells, adhesion of endothelial cells to matrix substrates and formation of capillary structures.

10. (Currently Amended) A method of treating atherosclerosis in a mammal comprising administering a therapeutically effective amount ~~of an active agent selected from the group consisting of a protein substance comprising all or part of a disintegrin domain of an adamalysin or a derivative thereof and~~ a nucleic acid molecule comprising a polynucleotide sequence coding a polypeptide comprising all or part of the disintegrin domain of an adamalysin or a derivative ~~thereof~~ of the disintegrin domain of an adamalysin to the mammal, wherein the disintegrin domain contains an RGD sequence and the polypeptide can inhibit migration and proliferation of endothelial cells, adhesion of endothelial cells to matrix substrates and formation of capillary structures.

11. (Currently Amended) A method of treating macular degeneration in a mammal comprising administering a therapeutically effective amount ~~of an active agent selected from the group consisting of a protein substance comprising all or part of a disintegrin domain of an adamalysin or a derivative thereof and~~ a nucleic acid molecule comprising a polynucleotide sequence coding a polypeptide comprising all or part of the disintegrin domain of an adamalysin or a derivative ~~thereof~~ of the disintegrin domain of an adamalysin to the mammal, wherein the disintegrin

domain contains an RGD sequence and the polypeptide can inhibit migration and proliferation of endothelial cells, adhesion of endothelial cells to matrix substrates and formation of capillary structures.

12. (Currently Amended) A method of treating psoriasis in a mammal comprising administering a therapeutically effective amount ~~of an active agent selected from the group consisting of a protein substance comprising all or part of a disintegrin domain of an adamalysin or a derivative thereof and~~ a nucleic acid molecule comprising a polynucleotide sequence coding a polypeptide comprising all or part of the disintegrin domain of an adamalysin or a derivative ~~thereof~~ of the disintegrin domain of an adamalysin to the mammal, wherein the disintegrin domain contains an RGD sequence and the polypeptide can inhibit migration and proliferation of endothelial cells, adhesion of endothelial cells to matrix substrates and formation of capillary structures.